Effects of Ruxolitinib on fibrosis in preclinical models of systemic sclerosis
International Immunopharmacology · 2023-03 · 116 · 109723
DOI: 10.1016/j.intimp.2023.109723 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023-03. Verfasst von Nessrine Bellamri und 7 weiteren Autor:innen. Beteiligte Einrichtung: Univ Rennes, CHU Rennes, INSERM, EHESP, IRSET (Institut de recherche en santé, environnement et travail) -UMR_S 1085, 35000 Rennes, France. Hauptthemen laut MEDLINE: Scleroderma, Systemic. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Institut National de la Santé et de la Recherche Médicale, Université de Rennes 1.
Abstract (Originalsprache)
Systemic sclerosis (SSc) is an autoimmune fibrotic disorder notably characterized by the production of antinuclear autoantibodies, which have been linked to an excess of apoptotic cells, normally eliminated by a macrophagic efferocytosis. As interferon (IFN) signature and phosphorylation of JAK-STAT proteins are hallmarks of SSc tissues, we tested the hypothesis that a JAK inhibitor, ruxolitinib, targeting the IFN signaling, could improve efferocytosis of IFN-exposed human macrophages in vitro as well as skin and lung fibrosis. In vivo, BLM- and HOCl-induced skin thickness and fibrosis is associated with an increase of caspase-3 positive dermal cells and a significant increase of IFN-stimulated genes expression. In BLM-SSc model, ruxolitinib prevented dermal thickness, fibrosis and significantly decreased the number of cleaved caspase-3 cells in the dermis. Ruxolitinib also improved lung architecture and fibrosis although IFN signature was not entirely decreased by ruxolitinib. In vitro, ruxolitinib improves efferocytosis capacity of human monocyte-differentiated macrophages exposed to IFN-γ or IFN-β. In human fibroblasts derived from lung (HLF) biopsies isolated from patients with idiopathic pulmonary fibrosis, the reduced mRNA expression of typical TGF-β-activated markers by ruxolitinib was associated with a decrease of the phosphorylation of SMAD2 /3 and STAT3. Our finding supports the anti-fibrotic properties of ruxolitinib in a systemic SSc mouse model and in vitro in human lung fibroblasts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Univ Rennes, CHU Rennes, INSERM, EHESP, IRSET (Institut de recherche en santé, environnement et travail) -UMR_S 1085, 35000 Rennes, France.
- Univ Rennes, CHU Rennes, INSERM, EHESP, IRSET (Institut de recherche en santé, environnement et travail) -UMR_S 1085, 35000 Rennes, France; Department of Internal Medicine, Rennes University Hospital, 35000 Rennes, Fran…
- Univ Rennes, CHU Rennes, INSERM, EHESP, IRSET (Institut de recherche en santé, environnement et travail) -UMR_S 1085, 35000 Rennes, France; Department of Respiratory Diseases, Competence Center for Rare Pulmonary Diseas…
- Univ Rennes, CHU Rennes, INSERM, EHESP, IRSET (Institut de recherche en santé, environnement et travail) -UMR_S 1085, 35000 Rennes, France. Electronic address: valerie.lecureur@univ-rennes1.fr.
Förderung
- Institut National de la Santé et de la Recherche Médicale
- Université de Rennes 1
Zitieren
APA
Bellamri, N., Lelong, M., Joannes, A., Le Tallec, E., Jouneau, S., Vernhet, L., Lescoat, A., & Lecureur, V. (2023). Effects of Ruxolitinib on fibrosis in preclinical models of systemic sclerosis. International Immunopharmacology, 116, 109723. https://doi.org/10.1016/j.intimp.2023.109723
Vancouver
Bellamri N, Lelong M, Joannes A, Le Tallec E, Jouneau S, Vernhet L, et al. Effects of Ruxolitinib on fibrosis in preclinical models of systemic sclerosis. International Immunopharmacology. 2023;116:109723. doi:10.1016/j.intimp.2023.109723
BibTeX
@article{Bellamri2023,
author = {Bellamri, Nessrine and Lelong, Marie and Joannes, Audrey and Le Tallec, Erwan and Jouneau, Stéphane and Vernhet, Laurent and Lescoat, Alain and Lecureur, Valérie},
title = {Effects of Ruxolitinib on fibrosis in preclinical models of systemic sclerosis},
journal = {International Immunopharmacology},
year = {2023},
volume = {116},
pages = {109723},
doi = {10.1016/j.intimp.2023.109723}
}
EUVIMED